This content is sponsored by
Philip Morris International
Philip Morris International
This content was produced by Boston Globe Media's
and paid for by the advertiser. The news and editorial departments of The Boston Globe had no role in
its production or display.
MOST POPULAR ON BOSTONGLOBE.COM
Based on what you've read recently, you might be interested in these stories
By BG BrandLab
| July 3, 2020
“Boston is one of the few places I have been where when you walk home after dinner, the casual couple you see on the street is more than likely talking about science,” says Thomas Westerling-Bui, director of scientific strategy at Aiforia, a Cambridge-based technology company that enables deep learning AI for image analysis.“You just need to park yourself in a corner in Boston and say you are a scientist and you will find a buddy.”
What is it about Boston that draws such significant scientific minds to the area? Read on to find out.
What scientists see in Boston
Westerling-Bui moved to Boston 12 years ago from Finland. He had interviews lined up in a few cities, but Boston was the only place he had more than one potential opportunity. He started his U.S career with a fellowship with Harvard Medical School and the Dana-Farber Cancer Institute. From the beginning, he was struck by the way different groups across Boston came together to tackle scientific questions. That sort of collaboration doesn’t happen everywhere, he notes.
In his experience, area experts are generally willing to help you, not just with discovery, but with bringing an idea from the lab to the market. If you don’t have the backing of an experienced network, you will make mistakes, and those mistakes can slow you down and compromise your progress, he says.
Colin Hill, cofounder of GNS Healthcare, an AI-driven precision medicine company developing a technology platform that discovers which patients respond to drugs and why, started his company at Cornell University. In 2006, he had a choice between moving his company to Boston, the San Francisco Bay Area, or Seattle. He chose Boston, in part because the area fosters a unique multidisciplinary approach.
“Physicists coming together with biologists and computer scientists — this is where Boston shines,” Hill says.
He notes Boston companies typically take on different types of challenges than Silicon Valley organizations do — time-consuming, complicated problems in areas like biomedical innovation and robotics. This type of work makes a huge difference in people’s lives, but it doesn’t happen overnight.
Paula Ragan, CEO of X4 Pharmaceuticals in Cambridge, agrees. She has lived in Boston for most of her life and describes it as “an amazing meeting of the minds.” People here are committed to using science to solve pressing problems, but the solutions they are working on could take 10-15 years to get to market, she explains.
Boston innovators are driven, highly skilled, and patient. They are also creative. “We think about things other people and places don’t think about,” says Ragan, citing Life Science Cares as an example. The organization rallies life science companies and industry leaders to donate time, services, or financial resources to organizations working tto eliminate the impact of poverty in the greater Boston area.
“The connection between life science and poverty might not be immediately clear, but poverty can negatively impact physical and mental health,” she says.
Capital, tech, and a long list of success stories
Chris Garabedian, CEO of Xontogeny, a Boston-based life sciences accelerator that partners with scientific founders and entrepreneurs to advance technologies through clinical development says the number of Boston-area companies that have received FDA approval of a drug “has grown considerably over the last five years.” He adds Boston continues to be one of the largest recipients of grant money and clinical research support across academic research institutions and leading medical centers.
“In many ways, Boston is a microcosm of the broader worldwide biotechnology ecosystem. Very few technologies or therapeutic areas are not touched by Boston institutions or companies that are located here,” he says.
Boston’s work on next-generation sequencing tools certainly helps shape science. CRISPR/Cas9 is the fastest, cheapest, and more precise genome editing tool to date, and it was pioneered by a team from the Broad Institute of MIT and Harvard.
Or take Cambridge-based biotech Moderna, dominating headlines for its progress on a potential vaccine for COVID-19, or Alnylam Pharmaceuticals, also in Cambridge, lauded for its progress exploring how RNAi therapeutics can be used to treat a wide-range of debilitating diseases. It has two approved products under its belt and five programs in late-stage clinical development.
Westerling-Bui adds it is hard to talk about Boston science without mentioning Vertex Therapeutics, a homegrown Boston company headquartered in Boston’s Innovation District. Vertex made waves for developing the first medicines to treat the underlying cause of cystic fibrosis (CF), a rare genetic disease. Westerling-Bui says Vertex encapsulates Boston science. “We are not only going for the obvious, ‘me too’ innovations, we are also tackling orphan diseases that don’t really get tackled at the same scale elsewhere,” he explains.
Careers for allEd Price, founder and president of Seqens North America, a Newburyport-based pharmaceutical manufacturer of new chemical entities (NCEs), active pharmaceutical ingredients (APIs), and other specialty chemical products, has worked closely with many local life science companies and says the list of Mass. success stories goes on and on. While he is impressed with the access to capital in the area and local government support of the industry, he is disappointed that the high-paying jobs the field generates do not always filter down.
“Not as much manufacturing is taking place in Massachusetts compared to other industries,” he says. “That limits the population that can participate in the life science boom.”
Price is an active proponent for reshoring and urges pharmaceutical companies to manufacture in the U.S., rather than overseas. This would create more jobs and help people from different backgrounds realize a career in science. The field shouldn’t be reserved for the privileged — it should create opportunities for everyone, just as the application of Boston science should benefit us all.
Sponsored by Philip Morris International
Our health care system has holes. Data and AI can help us fix them
Data and AI are transforming science and reducing health care costs.
7 ways advancements in science could impact your life
These real world applications of science change — and save — lives everyday.
Why it’s crucial that science be by all and for all
The best science is done by diverse groups of people and benefits everyone.
Science is vying to become the new MVP of sports
These discoveries are changing the game.
An ode to science: The biggest scientific breakthroughs of our generation
Six experts share which discoveries they think have made — and will make — the biggest impact.
How companies are using science to find the right hire
Whether you’re an employer or looking for employment, data science is your friend.
Clinical trials that came just in time
For scientists, clinical trials like these are a first try. For participants, they are often a last hope.
What you should know about the race for a COVID-19 vaccine, treatment, and testing
Boston is playing a big role in the long-term fight against COVID-19.
The future of medicine means redefining patient care
From gene sequencing to sensors, scientific discoveries will mean better prevention and treatment.